Merck to Present Phase 3 Cancer Trial Results at ESMO 2026
Merck & Co., Inc. (NYSE:MRK) announced that initial results from three pivotal Phase 3 clinical trials will feature during late-breaking Presidential Symposia at the European Society for Medical Oncology Congress 2026 in Madrid from October 23 to October 27. The drugmaker will showcase late-breaking data for intismeran, an investigational mRNA individualized neoantigen therapy developed with Moderna, combined with KEYTRUDA for post-surgery melanoma patients. Merck will also present Phase 3 data for sacituzumab tirumotecan in advanced endometrial cancer and KEYTRUDA monotherapy in first-line endometrial cancer, alongside over 90 additional cancer research abstracts.
The upcoming clinical disclosures highlight Merck's efforts to expand its oncology franchise beyond its established immunotherapies into next-generation treatments. By advancing novel personalized mRNA cancer vaccines and antibody-drug conjugates alongside expanded indications for existing therapies, the company aims to secure long-term growth across broader tumor types as existing treatment paradigms evolve.
Investors and analysts can track updates during Merck's dedicated oncology investor event scheduled for October 26 at 2:30 p.m. Eastern Time in Madrid. Shares of Merck traded slightly lower at $145.40 following the presentation schedule announcement.
Key points
- Merck will present initial Phase 3 results from three clinical trials at the ESMO Congress 2026 in Madrid from Oct. 23-27.
- Featured studies include mRNA therapy intismeran with KEYTRUDA in melanoma and sacituzumab tirumotecan in endometrial cancer.
- Over 90 additional abstracts covering more than 20 tumor types will be presented throughout the ESMO meeting.
- Merck will host an oncology investor event and webcast on Oct. 26 to provide updates on its strategy.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What oncology data will Merck present at ESMO 2026?
Merck will present first-time Phase 3 results for intismeran with KEYTRUDA in melanoma, sacituzumab tirumotecan in endometrial cancer, and KEYTRUDA monotherapy in first-line endometrial cancer, plus over 90 additional abstracts.
When is the Merck oncology investor event at ESMO 2026?
Merck will hold an oncology investor event on Monday, Oct. 26, 2026, at 2:30 p.m. Eastern Time (7:30 p.m. CET) via webcast.